TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees
Brief Summary: This cluster-randomized prospective study will evaluate the effect of hygiene-based intervention strategies on the incidence of overall SSTI and MRSA-associated SSTI among military trainees. The proposed interventions used singly or in combination include standardized training and education, and weekly chlorhexidine showers.


Options:
A: Arm Label: Symptom tracker users; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Symptom tracker users
B: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine
C: Arm Label: 1; Type: OTHER; Interventions: Other: Control | Arm Label: 2; Type: OTHER; Interventions: Device: Masks | Arm Label: 3; Type: OTHER; Interventions: Device: Masks & hand hygiene | Intervention Type: DEVICE; Name: Masks; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Masks & hand hygiene; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 1
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Soap | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Soap; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees
Brief Summary: This cluster-randomized prospective study will evaluate the effect of hygiene-based intervention strategies on the incidence of overall SSTI and MRSA-associated SSTI among military trainees. The proposed interventions used singly or in combination include standardized training and education, and weekly chlorhexidine showers.


Options:
A: Arm Label: Mask Intervention; Type: EXPERIMENTAL; Interventions: Device: Face mask, Behavioral: Face mask awareness | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Face mask; Assigned to Arm(s): Mask Intervention | Intervention Type: BEHAVIORAL; Name: Face mask awareness; Assigned to Arm(s): Mask Intervention
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: health education | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene, Device: face masks | Intervention Type: BEHAVIORAL; Name: hand hygiene; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: health education; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: face masks; Assigned to Arm(s): 3
C: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3804-250A lotion; Type: EXPERIMENTAL; Interventions: Drug: 3804-250A | Intervention Type: DRUG; Name: 3804-250A; Assigned to Arm(s): 3804-250A lotion
D: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees
Brief Summary: This cluster-randomized prospective study will evaluate the effect of hygiene-based intervention strategies on the incidence of overall SSTI and MRSA-associated SSTI among military trainees. The proposed interventions used singly or in combination include standardized training and education, and weekly chlorhexidine showers.


Options:
A: Arm Label: Vitamin D and gargling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3), Behavioral: Gargling | Arm Label: Vitamin D and general health advice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3) | Arm Label: Placebo and general health advice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Placebo and gargling; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Gargling, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): Vitamin D and gargling, Vitamin D and general health advice | Intervention Type: BEHAVIORAL; Name: Gargling; Assigned to Arm(s): Placebo and gargling, Vitamin D and gargling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo and gargling, Placebo and general health advice
B: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine
C: Arm Label: 1; Type: OTHER; Interventions: Other: Control | Arm Label: 2; Type: OTHER; Interventions: Device: Masks | Arm Label: 3; Type: OTHER; Interventions: Device: Masks & hand hygiene | Intervention Type: DEVICE; Name: Masks; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Masks & hand hygiene; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 1
D: Arm Label: Hand washing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hand washing | Arm Label: Disinfectant rubbing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Disinfectant rubbing | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Hand washing; Assigned to Arm(s): Hand washing | Intervention Type: BEHAVIORAL; Name: Disinfectant rubbing; Assigned to Arm(s): Disinfectant rubbing

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Making Accurate Problem Lists in the EHR
Brief Summary: The aim of this study is to identify patients with problem list gaps and intervene to correct these gaps by creating clinical decision support interventions that alert providers to likely problem list gaps and offer clinicians the opportunity to correct them. The investigators will randomize the clinics that will receive the intervention and formally evaluate the study after a period of 6 months for improved problem list completeness to determine the effectiveness of our intervention.


Options:
A: Arm Label: Clinic Quality Improvement + Behavioral Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic Quality Improvement + Behavioral Counseling | Arm Label: Clinic Quality Improvement + Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic Quality Improvement + Attention Control | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Behavioral Counseling; Assigned to Arm(s): Clinic Quality Improvement + Behavioral Counseling | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Attention Control; Assigned to Arm(s): Clinic Quality Improvement + Attention Control
B: Arm Label: Receive CDS intervention; Type: EXPERIMENTAL; Interventions: Other: MAPLE | Arm Label: No CDS intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MAPLE; Assigned to Arm(s): Receive CDS intervention
C: Arm Label: CDSS-D; Type: EXPERIMENTAL; Interventions: Other: Computerized Decision Support System for Depression (CDSS-D) | Arm Label: UC; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care (UC) | Intervention Type: OTHER; Name: Computerized Decision Support System for Depression (CDSS-D); Assigned to Arm(s): CDSS-D | Intervention Type: OTHER; Name: Usual Care (UC); Assigned to Arm(s): UC
D: Arm Label: Trained Clinicians; Type: EXPERIMENTAL; Interventions: Behavioral: Training | Arm Label: Non-trained Clinicians; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Non-volunteer Clinicians; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training; Assigned to Arm(s): Trained Clinicians

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Making Accurate Problem Lists in the EHR
Brief Summary: The aim of this study is to identify patients with problem list gaps and intervene to correct these gaps by creating clinical decision support interventions that alert providers to likely problem list gaps and offer clinicians the opportunity to correct them. The investigators will randomize the clinics that will receive the intervention and formally evaluate the study after a period of 6 months for improved problem list completeness to determine the effectiveness of our intervention.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HIT Intervention without feedback; Type: EXPERIMENTAL; Interventions: Other: 3-Part Intervention | Arm Label: HIT Intervention with feedback; Type: EXPERIMENTAL; Interventions: Other: 4-Part Intervention | Arm Label: Feedback only; Type: EXPERIMENTAL; Interventions: Other: 1-part intervention | Intervention Type: OTHER; Name: 3-Part Intervention; Assigned to Arm(s): HIT Intervention without feedback | Intervention Type: OTHER; Name: 4-Part Intervention; Assigned to Arm(s): HIT Intervention with feedback | Intervention Type: OTHER; Name: 1-part intervention; Assigned to Arm(s): Feedback only
B: Arm Label: A - coded unit ID; Type: EXPERIMENTAL; Interventions: Other: clinical decision support | Arm Label: B - coded unit ID; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: clinical decision support; Assigned to Arm(s): A - coded unit ID
C: Arm Label: Paper-based decision-support; Type: ACTIVE_COMPARATOR; Interventions: Other: Paper-based decision-support, Other: Pre-Assessment of practices | Arm Label: Smartphone-based decision-support; Type: ACTIVE_COMPARATOR; Interventions: Other: Smartphone-based decision-support, Other: Pre-Assessment of practices | Intervention Type: OTHER; Name: Smartphone-based decision-support; Assigned to Arm(s): Smartphone-based decision-support | Intervention Type: OTHER; Name: Paper-based decision-support; Assigned to Arm(s): Paper-based decision-support | Intervention Type: OTHER; Name: Pre-Assessment of practices; Assigned to Arm(s): Paper-based decision-support, Smartphone-based decision-support
D: Arm Label: Receive CDS intervention; Type: EXPERIMENTAL; Interventions: Other: MAPLE | Arm Label: No CDS intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MAPLE; Assigned to Arm(s): Receive CDS intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Brief Summary: The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selexipag | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Selexipag; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: UT-15C (oral treprositnil); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral treprostinil (UT-15C) Sustained Release Tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Oral treprostinil (UT-15C) Sustained Release Tablets; Assigned to Arm(s): UT-15C (oral treprositnil) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Inhaled treprostinil; Type: EXPERIMENTAL; Interventions: Drug: Inhaled treprostinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo inhalation solution | Intervention Type: DRUG; Name: Inhaled treprostinil; Assigned to Arm(s): Inhaled treprostinil | Intervention Type: DRUG; Name: Placebo inhalation solution; Assigned to Arm(s): Placebo
D: Arm Label: ACT-293987 (NS-304) and matching placebo; Type: EXPERIMENTAL; Interventions: Device: ACT-293987 (NS-304) | Intervention Type: DEVICE; Name: ACT-293987 (NS-304); Assigned to Arm(s): ACT-293987 (NS-304) and matching placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
Brief Summary: The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bosentan, Other: Placebo | Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Bosentan, Drug: Sildenafil Citrate | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Sildenafil Citrate; Assigned to Arm(s): Active
B: Intervention Type: DRUG; Name: Bosentan and Sildenafil; Assigned to Arm(s): N/A
C: Arm Label: 20 mg tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 40 mg tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 20 mg tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 40 mg tadalafil
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selexipag | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Selexipag; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial to Compare Intensive Management vs Standard Care in Early Psoriatic Arthritis
Brief Summary: The purpose of this study is to investigate whether tight control of patients with newly diagnosed psoriatic arthritis (consisting of regular 4 weekly objective assessment of disease activity and protocol-led intensive treatment) can improve outcome as opposed to standard care (usually 3 monthly reviews with no objective outcome measures and no protocol for treatment). The principle hypothesis of this study is that tight control of inflammation in psoriatic arthritis using a treatment protocol and pre-defined objective targets for treatment will lead to an improvement in patients' disease activity and a reduction in radiological joint damage.


Options:
A: Arm Label: Intensive management; Type: EXPERIMENTAL; Interventions: Drug: Intensive management or Tight control | Arm Label: Standard management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard management - Control group | Intervention Type: DRUG; Name: Intensive management or Tight control; Assigned to Arm(s): Intensive management | Intervention Type: DRUG; Name: Standard management - Control group; Assigned to Arm(s): Standard management
B: Arm Label: Infliximab + methotrexate (IFX + MTX); Type: EXPERIMENTAL; Interventions: Drug: Infliximab + methotrexate (IFX + MTX) | Arm Label: Methotrexate (MTX); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: Infliximab + methotrexate (IFX + MTX); Assigned to Arm(s): Infliximab + methotrexate (IFX + MTX) | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): Methotrexate (MTX)
C: Arm Label: 10 mg Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 15 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 20 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 25 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 10 mg Methotrexate (MTX), 15 mg MTX, 20 mg MTX, 25 mg MTX
D: Arm Label: Treatment Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Golimumab | Arm Label: Treatment Group 2: Golimumab; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Golimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment Group 1: Placebo, Treatment Group 2: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Treatment Group 1: Placebo, Treatment Group 2: Golimumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of a Preoperative Single-dose Methylprednisolone on the Postoperative Rehabilitation After Abdominal Hysterectomy: A Prospective, Double Blinded, Placebo Controlled Study
Brief Summary: The purpose of this study is to evaluate the effect of 125 mg methylprednisolone, given intravenously 60-90 minutes before abdominal surgery,on the postoperative rehabilitation after abdominal hysterectomy.Sodium Chloride is the placebo. The following parameters are registered:

1. Pain 3, 6 and 24 hours postoperatively and 2-7 days after surgery.
2. The postoperative use of additional analgesics.
3. Inflammatory parameters before and after surgery.
4. Time until mobilization.
5. Time until discharge.


Options:
A: Arm Label: The study group (Gr. D); Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone, Drug: Ondansetron | Arm Label: the control group (Gr. N); Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Sodium Chloride Injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): The study group (Gr. D) | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): The study group (Gr. D) | Intervention Type: DRUG; Name: 0.9% Sodium Chloride Injection; Assigned to Arm(s): the control group (Gr. N)
B: Arm Label: Methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone 125mg | Arm Label: placebo/sodium chloride; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 2 ml | Intervention Type: DRUG; Name: Methylprednisolone 125mg; Assigned to Arm(s): Methylprednisolone | Intervention Type: DRUG; Name: Sodium Chloride 2 ml; Assigned to Arm(s): placebo/sodium chloride
C: Intervention Type: DRUG; Name: MK0869, aprepitant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: ondansetron IV; Assigned to Arm(s): N/A
D: Arm Label: Aprepitant group; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aprepitant; Assigned to Arm(s): Aprepitant group | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial to Test the Efficacy of a Tailored Intensive Smoking Cessation Intervention in Persons With HIV (PWHs)
Brief Summary: The purpose of this study is to determine whether an intensive, eight session behavioral intervention is superior to standard care in achieving abstinence from cigarettes in smokers living with HIV/AIDS.


Options:
A: Arm Label: Standard support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support | Arm Label: Proactive telephone support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support | Arm Label: Standard support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Arm Label: Proactive support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Intervention Type: BEHAVIORAL; Name: Proactive telephone support; Assigned to Arm(s): Proactive support & offer NRT, Proactive telephone support | Intervention Type: BEHAVIORAL; Name: Reactive (standard) telephone support; Assigned to Arm(s): Standard support, Standard support & offer NRT | Intervention Type: DRUG; Name: Offer of voucher for cost-free Nicotine Replacement Therapy; Assigned to Arm(s): Proactive support & offer NRT, Standard support & offer NRT
B: Arm Label: Intensive behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Positively Smoke Free | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Positively Smoke Free; Assigned to Arm(s): Intensive behavioral intervention | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care
C: Arm Label: Positive psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Psychotherapy for smoking cessation, Drug: Nicotine polacrilex, Behavioral: Behavioral smoking cessation treatment | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Behavioral: Relaxation training, Behavioral: Behavioral smoking cessation treatment | Intervention Type: BEHAVIORAL; Name: Positive Psychotherapy for smoking cessation; Assigned to Arm(s): Positive psychotherapy | Intervention Type: DRUG; Name: Nicotine polacrilex; Assigned to Arm(s): Positive psychotherapy, Standard treatment | Intervention Type: BEHAVIORAL; Name: Relaxation training; Assigned to Arm(s): Standard treatment | Intervention Type: BEHAVIORAL; Name: Behavioral smoking cessation treatment; Assigned to Arm(s): Positive psychotherapy, Standard treatment
D: Arm Label: 1; Type: OTHER; Interventions: Other: Counselor-Initiated Tobacco Quit Line | Arm Label: 2; Type: OTHER; Interventions: Other: Self-Paced Tobacco Quit Line | Intervention Type: OTHER; Name: Counselor-Initiated Tobacco Quit Line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Self-Paced Tobacco Quit Line; Assigned to Arm(s): 2

Answer: B